Efficacy of methotrexate in rheumatoid arthritis

Rheumatology (United Kingdom)

Volumn 34, Issue , 1995, Pages 43-48

  Weinblatt, M E ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Antifolate; Comparative study; Methotrexate; Rheumatoid arthritis

Indexed keywords

EID: 84960582159     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/XXXIV.suppl_4.43     Document Type: Article

References (49)

1. Farber S, Diamond LK, Mercer RD, Sylvester RF, Wolff JA. Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid (aminopterin). N Engl J Med 1948;238:787–93.
2. Gubner R, August S, Ginsberg V. Therapeutic suppression of tissue reactivity. II. Effect of aminopterin in rheumatoid arthritis and psoriasis. Am J Med Sci 1951;22:176–82.
3. Weinstein GD, Frost P. Methotrexate for psoriasis. A new therapeutic schedule. Arch Dermatol 1971;103:33–8.
4. Black RL, O’Brien WM, Van Scott EJ, Auerbach R, Eisen AZ, Bunim JJ. Methotrexate therapy in psoriatic arthritis. Double-blind study on 21 patients. J Am Med Assoc 1964;189:743–7.
5. Willkens RF, Williams HJ, Ward JR et al. Randomized, double-blind, placebo-controlled trial of low-dose pulse methotrexate in psoriatic arthritis. Arthritis Rheum 1984;27:376–81.
6. Hoffmeister RT. Methotrexate in rheumatoid arthritis. Arthritis Rheum 1972;15:114 (abstract).
7. Willkens RF, Watson MA. Methotrexate: a perspective of its use in the treatment of rheumatic diseases. J Lab Clin Med 1982;100:314–21.
8. Hoffmeister RT. Methotrexate therapy in rheumatoid arthritis: 15 years experience. Am J Med 1983;75:69–73.
9. Steinsson K, Weinstein A, Korn J, Abeles M. Low-dose methotrexate in rheumatoid arthritis. J Rheumatol 1982;9:860–6.
10. Weinstein A, Marlowe S, Korn J, Farouhar F. Low-dose methotrexate treatment of rheumatoid arthritis. Long-term observations. Am J Med 1985;79:331–7.
11. Michaels RM, Nashel DJ, Leonard A, Sliwinski AJ, Derbes SJ. Weekly intravenous methotrexate in the treatment of rheumatoid arthritis. Arthritis Rheum 1982;25:339–41.
12. Thompson RN, Watts C, Edelman J, Esdaile J, Russell AS. A controlled two-centre trial of parenteral methotrexate therapy for refractory rheumatoid arthritis. J Rheumatol 1984;11:760–3.
13. Weinblatt ME, Coblyn JS, Fox DA et al. Efficacy of low-dose methotrexate in rheumatoid arthritis. N Engl J Med 1985;312:818–22.
14. Williams HJ, Willkens RF, Samuelson CO, Jr et al. Comparison of low-dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis. A controlled clinical trial. Arthritis Rheum 1985;25:721–30.
15. Andersen PA, West SG, O’Dell JR, Via CS, Claypool RG, Kotzin BL. Weekly pulse methotrexate in rheumatoid arthritis. Clinical and immunologic effects in a randomized, double-blind study. Ann Intern Med 1985;103:489–96.
16. Tugwell P, Bennett K, Gent M. Methotrexate in rheumatoid arthritis. Indications, contraindications, efficacy, and safety. Ann Intern Med 1987;107:358–66.
17. Kremer JM, Rynes RI, Bartholomew LE. Severe flare of rheumatoid arthritis after discontinuation of long-term methotrexate therapy. Double-blind study. Am J Med 1987;82:781–6.
18. Szanto E. Low-dose methotrexate in rheumatoid arthritis: effect and tolerance. An open trial and a double-blind randomized study. Scand J Rheumatol 1986;15:97–102.
19. Hamdy H, McKendry RJ, Mierins E, Liver JA. Low-dose methotrexate compared with azathioprine in the treatment of rheumatoid arthritis. A twenty-four-week controlled clinical trial. Arthritis Rheum 1987;30:361–8.
20. Arnold MH, O’Callaghan J, McCredie M, Beller EM, Kelly DE, Brooks PM. Comparative controlled trial of low-dose weekly methotrexate versus azathioprine in rheumatoid arthritis: 3-year prospective study. Br J Rheumatol 1990;29:120–5.
21. Jeurissen MEC, Boerbooms AMT, van de Putte LBA et al. Methotrexate versus azathioprine in the treatment of rheumatoid arthritis: A forty-eight-week randomized, double-blind trial. Arthritis Rheum 1991;34:961–72.
22. Suarez-Almazor ME, Fitzgerald A, Grace M, Russell AS. A randomized controlled trial of parenteral methotrexate compared with sodium aurothiomalate (Myochrysine) in the treatment of rheumatoid arthritis. J Rheumatol 1988;15:753–6.
23. Morassut P, Goldstein R, Cyr M, Karsh J, McKendry RJ. Gold sodium thiomalate compared to low-dose methotrexate in the treatment of rheumatoid arthritis—a randomized, double-blind 26-week trial. J Rheumatol 1989;16:302–6.
24. Rau R, Herborn G, Karger T, Menninger H, Elhardt D, Schmitt J. A double-blind randomized parallel trial of intramuscular methotrexate and gold sodium thiomalate in early erosive rheumatoid arthritis. J Rheumatol 1991;18:328–33.
25. Weinblatt ME, Kaplan H, Germain BF et al. Low-dose methotrexate compared with auranofin in adult rheumatoid arthritis. A thirty-six-week, double-blind trial. Arthritis Rheum 1990;33:330–8.
26. Cohen S, Rutstein J, Luggen M et al. Comparison of the safety and efficacy of cyclosporin A and methotrexate in refractory rheumatoid arthritis: A randomized, multi-centered placebo-controlled trial. Arthritis Rheum 1993;36:S56 (abstract).
27. Felson DT, Anderson JJ, Meenan RF. The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis: Results of two metaanalyses. Arthritis Rheum 1990;33:1449–61.
28. Felson DT, Anderson JJ, Meenan RF. Use of short-term efficacy/toxicity tradeoffs to select second-line drugs in rheumatoid arthritis. A meta-analysis of published clinical trials. Arthritis Rheum 1992;35:1117–25.
29. Kremer JM, Phelps CT. Long-term prospective study of the use of methotrexate in rheumatoid arthritis. Update after a mean of 90 months. Arthritis Rheum 1992;35:138–45.
30. Weinblatt ME, Weissman BN, Holdsworth DE et al. Long-term prospective study of methotrexate in the treatment of rheumatoid arthritis. Eighty-four-month update. Arthritis Rheum 1992;35:129–37.
31. Hanrahan PS, Scrivens GA, Russell AS. Prospective long-term follow-up of methotrexate therapy in rheumatoid arthritis: toxicity, efficacy and radiological progression. Br J Rheumatol 1989;28:147–53.
32. Sany J, Anaya JM, Lussiez V, Couret M, Combe B, Daures J-P. Treatment of rheumatoid arthritis with methotrexate: A prospective open long-term study of 191 cases. J Rheumatol 1991;18:1323–7.
33. Weinblatt ME, Kaplan H, Germain BF et al. Methotrexate in rheumatoid arthritis. A 5-year prospective multicenter study. Arthritis Rheum 1994;37:1492–8.
34. Paulus HE, Egger MJ, Ward JR, Williams HJ. Analysis of improvement in individual rheumatoid arthritis patients treated with disease-modifying antirheumatic drugs, based on the findings in patients treated with placebo. The Cooperative Systemic Studies of Rheumatic Diseases Group. Arthritis Rheum 1990;33:477–84.
35. Fehlauer CS, Carson CW, Cannon GW et al. Methotrexate therapy in rheumatoid arthritis: 2-year retrospective follow-up study. J Rheumatol 1989;16:307–12.
36. Alarcón GS, Tracy IC, Blackburn WD, Jr. Methotrexate in rheumatoid arthritis. Toxic effects as the major factor in limiting long-term treatment. Arthritis Rheum 1989;32:671–6.
37. Pincus T, Marcum SB, Callahan LF. Long-term drug therapy for rheumatoid arthritis in seven rheumatology private practices II. Second-line drugs and prednisone. J Rheumatol 1992;19:1885–94.
38. Wolfe F, Hawley DJ, Cathey MA. Termination of slow acting antirheumatic therapy in rheumatoid arthritis: A 14-year prospective evaluation of 1017 consecutive starts. J Rheumatol 1990;17:994–1002.
39. Morand EF, McCloud PI, Littlejohn GO. Life table analysis of 879 treatment episodes with slow acting antirheumatic drugs in community rheumatology practice. J Rheumatol 1992;19:703–8.
40. Buchbinder R, Hall S, Sambrook PN et al. Methotrexate therapy in rheumatoid arthritis: A life table review of 587 patients treated in community practice. J Rheumatol 1993;20:639–44.
41. Furst DE, Koehnke R, Burmeister LF, Kohler J, Cargill I. Increasing methotrexate effect with increasing dose in the treatment of resistant rheumatoid arthritis. J Rheumatol 1989;16:313–20.
42. Gabriel S, Creagan E, O’Fallon WM, Jaquith J, Bunch T. Treatment of rheumatoid arthritis with higher dose intravenous methotrexate. J Rheumatol 1990;17:460–5.
43. Kremer JM, Lee JK. The safety and efficacy of the use of methotrexate in long-term therapy for rheumatoid arthritis. Arthritis Rheum 1986;29:822–31.
44. Kremer JM, Lee JK. A long-term prospective study of the use of methotrexate in rheumatoid arthritis. Update after a mean of fifty-three months. Arthritis Rheum 1988;31:577–84.
45. Weinblatt ME, Trentham DE, Fraser PA et al. Long-term prospective trial of low-dose methotrexate in rheumatoid arthritis. Arthritis Rheum 1988;31:167–75.
46. Reykdal S, Steinsson K, Sigurjonsson K, Brekkan A. Methotrexate treatment of rheumatoid arthritis: effects on radiological progression. Scand J Rheumatol 1989;18:221–6.
47. Jeurissen MEC, Boerbooms AMT, van de Putte LBA, Doesburg WH, Lemmens AM. Influence of methotrexate and azathioprine on radiologic progression in rheumatoid arthritis. A randomized, double-blind study. Ann Intern Med 1991;114:999–1004.
48. Weinblatt ME, Polisson R, Blotner SD et al. The effects of drug therapy on radiographic progression of rheumatoid arthritis. Results of a 36-week randomized trial comparing methotrexate and auranofin. Arthritis Rheum 1993;36:613–19.
49. López-Méndez A, Daniel WW, Reading JC, Ward JR, Alarcón GS. Radiographic assessment of disease progression in rheumatoid arthritis patients enrolled in the cooperative systematic studies of the rheumatic diseases program: randomized clinical trial of methotrexate, auranofin, or a combination of the two. Arthritis Rheum 1993;36:1364–9.